EUCTR2017-005130-27-GB进行中（未招募）1 期
ow-dose interleukin-2 for the reduction of vascular inflammation in Acute Coronary Syndromes (IVORY) - IVORY
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge0 个研究点目标入组 60 人开始时间: 2019年5月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be included in the trial the participant must meet the following criteria:
- •- Able to provide written informed consent to participate.
- •- Age between 18 and 85
- •- Current admission (on the screening visit) with an ACS with symptoms suggestive of mycardial ischaemia lasting 10 minutes or longer with the patient at rest or with minimal effort and EITHER i) elevated levels of TnI on admission OR ii) dynamic changes in ECG (new ST-T changes, T-wave inversion).
- •- Where applicable, to be included in the trial women must be: i. Postmenopausal (for the purposes of this trial, postmenopausal is defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms) OR ii. Have had a documented hysterectomy and/or bilateral oophorectomy OR sterilisation OR iii. Peri-menopausal with a negative pregnancy test at screening (for the purposes of this trial, perimenopausal is defined as women with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms, irregular periods). These women will be expected to comply with the use of contraception for the duration of the trial and undergo additional pregnancy tests during and after treatment.
- •- High sensitivity C-reactive protein of >2 mg/L at screening
- •- Willingness and possibility to start dosing within 8 days from initial date of admission to the primary hospital for ACS
- •- Able to comply with all trial mandated visits
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •- Current presentation (at screening) with cardiogenic shock (systolic blood pressure <80 mm Hg, that is unresponsive to fluids, or necessitates administration of catecholamines)
- •- Current presentation with cardiac arrest
- •- Signs or symptoms of active infection requiring intravenous antibiotic treatment at screening
- •- History of malignancies requiring active treatment (However, patients with a history of treated localised basal or squamous cell skin cancer are not excluded from participation in this trial)
- •- History of solid organ transplantation or other bone marrow transplantation
- •- History of recurrent epileptic seizures in the previous 4 years; repetitive or difficult to control seizures, coma or toxic psychosis lasting >48 hours
- •- Uncontrolled hypotension (Systolic BP (SBP)<80mmHg or DBP<50mmHg) OR uncontrolled hypertension (SBP>180 or DBP>120 mmHg) at screening
- •- Average corrected QT interval (QTc) > 450 msecs using Bazett’s formula from average of triplicate ECGs (or > 480 msecs if bundle branch block)
- •- Renal impairment defined as Creatinine clearance [Cockcroft-Gault] <45ml/min at screening
- •- Liver dysfunction (defined as ALT > 2xULN) at screening
- •- Evidence of cholestasis defined as elevated Total Bilirubin Levels, (TBL > 1.5 x ULN) and Alkaline Phosphatase, ALP (ALP > 1.5 x ULN), at screening
- •- Known hypothyroidism or hyperthyroidism
- •- Known autoimmune disease requiring active immunosuppressive treatment
- •- Any regular oral or intravenous immunosuppressive treatment including prednisolone, hydrocortisone or disease modifying drugs. [Inhaled or topical steroids are permissible]
- •- Patients on cytotoxic drugs and interferon-alpha
- •- Known Type 1 or Type 2 diabetes mellitus
- •- Contraindication to IL-2 treatment or hypersensitivity to IL-2 or to any of its excipients
- •- Participation in a previous research trial in the last 3 years which involved exposure to significant ionising radiation (i.e. cumulative research radiation dose >5 mSv)
- •- Participation in a clinical trial where the patient has received a drug or new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of the drug (whichever is longer) prior to the first dose of trial medication, Visit 3 (Day 1).
- •- Any medical history or clinically relevant abnormality that is deemed by the principal investigator/delegate to make the patient ineligible for inclusion because of a safety concern
- •- Pregnant women or breastfeeding women.
研究者
相似试验
招募中
不适用
Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up StudyAcute Coronary SyndromesNCT06427694Cambridge University Hospitals NHS Foundation Trust60
进行中（未招募）
1 期
A Phase I-IIa trial on low-dose IL-2 (Aldesleukin) treatment for immunological dysregulation in common variable immunodeficiency (CVID)autoimmune enteropathy (AIE) in common variable immunodeficiency (CVID).MedDRA version: 19.0Level: PTClassification code 10021449Term: Immunodeficiency common variableSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 19.0Level: LLTClassification code 10017922Term: Gastroenteropathy NOSSystem Organ Class: 100000004856EUCTR2015-003369-27-DEniversitätsklinikum Freiburg6
招募中
1 期
A Phase I-IIa trial on low-dose IL-2 (Aldesleukin) treatment for immunological dysregulation in common variable immunodeficiency (CVID)D83Common variable immunodeficiencyDRKS00010424niversitätsklinikum Freiburg6
已完成
2 期
Phase II clinical trial of interleukin-2, interferon-alpha and tegafur uracil therapy for advanced renal cell canceradvanced renal cell cancerJPRN-UMIN000002222Department of Urology Faculty of Medicine50
终止
2 期
Interleukin-2 in Metastatic MelanomaMelanoma MetastaticNCT01702896Western Regional Medical Center8